吡柔比星与表柔比星在表浅性膀胱癌术后灌注预防复发中的循证药物经济学研究

doi:10.5246/jcps.2016.02.016

中国药学(英文版) ›› 2016, Vol. 25 ›› Issue (2): 145-149.DOI: 10.5246/jcps.2016.02.016

吡柔比星与表柔比星在表浅性膀胱癌术后灌注预防复发中的循证药物经济学研究

马莉莉¹, 林其敏¹, 韩晟², 于飞¹, 史录文^1,2*

1. 北京大学医学部药学院, 北京 100191
2. 北京大学医学部医药管理国际研究中心, 北京 100191

收稿日期:2015-09-08 修回日期:2015-10-09 出版日期:2016-02-29 发布日期:2015-10-29
通讯作者: Tel.: 86-10-82805019, E-mail: shilu@bjmu.edu.cn

Evidence-based pharmacoeconomic research of pirarubicin and epirubicin as prophylaxis for recurrence in patients with superficial bladder tumors by bladder instillation after transurethral resection of a bladder tumor

Lili Ma¹, Qimin Lin¹, Sheng Han², Fei Yu¹, Luwen Shi^1,2*

1. School of Pharmaceutical Sciences, Peking University Health Science Center, Beijing 100191, China
2. International Research Center of Medicinal Administration, Peking University Health Science Center, Beijing 100191, China

Received:2015-09-08 Revised:2015-10-09 Online:2016-02-29 Published:2015-10-29
Contact: Tel.: 86-10-82805019, E-mail: shilu@bjmu.edu.cn

摘要/Abstract

摘要：

本文综合评价吡柔比星与表柔比星在表浅性膀胱癌术后灌注预防复发中的有效性与经济性。通过文献研究, 对吡柔比星与表柔比星在表浅性膀胱癌术后灌注预防复发中的有效性进行规范化系统评价; 结合专家意见、文献及获得的成本数据对吡柔比星与表柔比星进行药物经济学分析。结果表明, 文献分析及专家意见都证实吡柔比星与表柔比星膀胱灌注对预防表浅性膀胱癌术后复发的效果并无差异; 若按照临床实践及文献研究中常用的灌注方案进行灌注, 吡柔比星与表柔比星的经济学评价需按照原研药和仿制药分别讨论, 原研药吡柔比星比表柔比星更具经济学优势; 仿制药表柔比星比吡柔比星更具经济学优势。吡柔比星与表柔比星膀胱灌注对预防表浅性膀胱癌术后复发的效果并无统计学差异; 吡柔比星与表柔比星经济学优势需分别讨论。

关键词: 吡柔比星, 表柔比星, 经济性, 表浅性膀胱癌

Abstract:

In the present study, we aimed to evaluate the efficiency and cost of pirarubicin (THP) and epirubicin (EPI) as prophylaxis for recurrence in patients with superficial bladder tumors by bladder instillation after transurethral resection of a bladder tumor (TUR-BT). Standardized evaluation was performed by analyzing research papers. Moreover, expert opinions, studies and cost data were combined to evaluate cost of THP and EPI. With systematic review and expert opinions, we confirmed that THP and EPI were not statistically different when they were used as prophylaxis for recurrence in patients with superficial bladder tumors by bladder instillation after TUR-BT. Moreover, the cost evaluation of THP and EPI needs to be separately discussed according to original/generic drug. The original drug THP had more cost advantages than EPI, while generic EPI had more cost advantages than THP.

Key words: Pirarubicin, Epirubicin, Cost, Superficial bladder cancer

中图分类号:

R951

Supporting:

马莉莉, 林其敏, 韩晟, 于飞, 史录文. 吡柔比星与表柔比星在表浅性膀胱癌术后灌注预防复发中的循证药物经济学研究[J]. 中国药学(英文版), 2016, 25(2): 145-149.

Lili Ma, Qimin Lin, Sheng Han, Fei Yu, Luwen Shi. Evidence-based pharmacoeconomic research of pirarubicin and epirubicin as prophylaxis for recurrence in patients with superficial bladder tumors by bladder instillation after transurethral resection of a bladder tumor[J]. Journal of Chinese Pharmaceutical Sciences, 2016, 25(2): 145-149.

[1]	彭词艳, 陈景, 李斯妮, 李健和, 彭六保. 哌柏西利联用来曲唑对比多西他赛联用表柔比星一线治疗晚期乳腺癌的循证药物经济学评价[J]. 中国药学(英文版), 2023, 32(3): 214-222.
[2]	韩晟, 王宽, 濮润, 史录文^*. 软聚硅酮泡沫吸收敷料治疗压疮的药物经济学研究[J]. , 2013, 22(5): 456-460.
[3]	周欣, 陈利华, 翟所迪^*. 不同输液包装对药液残留量和输液治疗的经济性和有效性的影响[J]. , 2010, 19(2): 125-129.

吡柔比星与表柔比星在表浅性膀胱癌术后灌注预防复发中的循证药物经济学研究

Evidence-based pharmacoeconomic research of pirarubicin and epirubicin as prophylaxis for recurrence in patients with superficial bladder tumors by bladder instillation after transurethral resection of a bladder tumor

RichHTML

PDF (PC)

可视化

被引次数

摘要/Abstract

引用本文

使用本文

参考文献

相关文章 3

编辑推荐

Metrics

本文评价